Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy

Shiratori, Yasushi; Imazeki, Fumio; Moriyama, Mitsuhiko; Yano, Michitami; Arakawa, Yasuyuki; Yokosuka, Osamu; Kuroki, Tetsuo; Nishiguchi, Shuhei; Sata, Michio; Yamada, G; Fujiyama, Shigetoshi; Yoshida, Haruhiko; Omata, Masao

doi:10.7326/0003-4819-132-7-200004040-00002

Cited by 694 publications

(594 citation statements)

References 17 publications

Supporting

Mentioning

555

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, liver histology revealed an improvement in staging and in activity after the IFN therapy whencomparedto the images before the therapy. The images were also found to be similar to the case previously reported (9,10).…”

Section: Discussionsupporting

confidence: 77%

Interferon Therapy for Hapatitis C Virus (HCV)-related Advanced Chronic Hepatitis after Treatment of Recurrent Hepatocellular Carcinoma: A Successful Case.

Kudo

Terao

Arita³

et al. 2002

Intern. Med.

View full text Add to dashboard Cite

A complete response was obtained by interferon (IFN) therapy for hepatitis C virus (HCV)-related advanced chronic hepatitis after curative treatment of initial and recurrent hepatocellular carcinoma (HCC). The patient is alive 73 months after diagnosis of initial HCCand is in a tumor-free state 53 months after diagnosis of the last HCC. This case suggest that it is possible to suppress recurrence and to prolong the life of patients with HCV-related advanced chronic hepatitis, if a complete response is obtained by means of IFN therapy after the curative treatment of the recurrent HCC. (Internal Medicine 41 : 202-206, 2002)

show abstract

Section: Discussionsupporting

confidence: 77%

Interferon Therapy for Hapatitis C Virus (HCV)-related Advanced Chronic Hepatitis after Treatment of Recurrent Hepatocellular Carcinoma: A Successful Case.

Kudo

Terao

Arita³

et al. 2002

Intern. Med.

View full text Add to dashboard Cite

show abstract

“…This effect is more pronounced in patients who achieve a sustained virologic response. Moreover, there is evidence that specific antiviral therapy can reduce progress of hepatic fibrosis in patients with nonsustained virologic response [50,51]. In future, a study population enrolling a homogenous group of HCV and NASH patients at high risk for fibrosis progression compared with those who are not would be ideal to substantiate treatment differences in both groups.…”

Section: Therapy Of Liver Fibrosismentioning

confidence: 99%

Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL)

et al. 2008

Self Cite

View full text Add to dashboard Cite

show abstract

“…The elimination of HCV will prevent the progression of chronic hepatitis and associated complications 5. Several studies have reported that achievement of SVR results in the resolution of liver fibrosis6, 7 and a decreased incidence of HCC 8. However, development of HCC is sometimes seen even in patients who achieve SVR after DAA treatment, indicating the need for continuous surveillance for HCC after the eradication of HCV 9, 10, 11, 12.…”

Section: Introductionmentioning

confidence: 99%

Liver stiffness measurement predicts hepatocellular carcinoma development in patients treated with direct‐acting antivirals

et al. 2017

View full text Add to dashboard Cite

Background and AimPredictive factors for hepatocarcinogenesis following eradication of hepatitis C virus by direct‐acting antivirals (DAAs) are unknown. The aim of the study was to investigate the relationships between liver stiffness (LS) using acoustic radiation force impulse (ARFI) erastograghy and the development of hepatocellular carcinoma (HCC) in patients who achieved sustained virological response (SVR) treated with DAA.MethodsIn this prospective study, we enrolled 263 hepatitis C patients with SVR who underwent ARFI before DAA treatment. Thirty patients had previous HCC.ResultsThe median LS value according to ARFI measurements was 1.34 m/s (range: 0.67–4.35). During the follow‐up period (median: 18.1 months), development of HCC occurred in 19 patients (7.2%; HCC occurrence in 7 patients and HCC recurrence in 12 patients). By multivariate Cox regression analysis, HCC history (hazard ratio [HR]: 10.634; 95% confidence interval [CI]: 4.13–27.37; P = 0.001), older age (HR: 4.638; 95% CI: 1.63–13.61; P = 0.004) and higher total bilirubin levels (HR: 4.189; 95% CI: 1.66–10.60; P = 0.002) were independent predictors for the development of HCC, and higher LS value (≥1.73 m/s) at baseline was an independent predictor for HCC occurrence (HR: 8.350; 95% CI: 1.62–43.09; P = 0.011). The cumulative recurrence of HCC was statistically similar according to the degree of LS in patients who were previously treated for HCC.ConclusionThe LS value at baseline is useful for predicting HCC occurrence. Thus, even if SVR is achieved, patients with higher LS at baseline must be followed carefully for HCC occurrence.

show abstract

Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy

Abstract: Although the time between biopsies partly affected the patient's clinical course, the differences observed here suggest that in patients with chronic hepatitis C, regression of fibrosis is associated with sustained virologic response to interferon therapy.

Cited by 694 publications

References 17 publications

Interferon Therapy for Hapatitis C Virus (HCV)-related Advanced Chronic Hepatitis after Treatment of Recurrent Hepatocellular Carcinoma: A Successful Case.

Interferon Therapy for Hapatitis C Virus (HCV)-related Advanced Chronic Hepatitis after Treatment of Recurrent Hepatocellular Carcinoma: A Successful Case.

Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL)

Liver stiffness measurement predicts hepatocellular carcinoma development in patients treated with direct‐acting antivirals

Contact Info

Product

Resources

About